Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid peptide developed by Eli Lilly. It is a dual agonist that activates both the GLP-1 receptor and the GIP receptor in a single molecule. The licensed drug is sold by Eli Lilly as Mounjaro (FDA-approved 2022 for type 2 diabetes) and Zepbound (FDA-approved 2023 for chronic weight management). New-U supplies research-grade tirzepatide under the GLP-1 RC-T SKU as a laboratory reagent only, not a finished medicinal product.

What does tirzepatide do?

It activates two metabolic receptors simultaneously. GLP-1 receptor activation slows gastric emptying, suppresses appetite via central nervous system signalling, and improves insulin secretion. GIP receptor activation supports glucose-dependent insulin release and lipid handling in adipose tissue. The dual mechanism produces larger weight-loss and HbA1c reductions than single-receptor GLP-1 agonists like semaglutide in head-to-head trials.

How much weight loss did tirzepatide achieve in trials?

SURMOUNT-1 (the Phase 3 obesity trial published in NEJM, 2022) reported mean weight loss of ~22.5% in the 15mg arm at 72 weeks vs ~3% placebo. About 36% of the 15mg cohort lost 25% or more of body weight. SURPASS-2 (T2D trial) showed superiority over semaglutide on both HbA1c and weight loss. These are reported clinical-trial outcomes in approved-drug populations, not predictions for research-compound use.

Is tirzepatide FDA approved?

Yes - as a licensed medicinal product. Mounjaro was FDA-approved in May 2022 for type 2 diabetes; Zepbound was approved in November 2023 for chronic weight management in adults with obesity. Both are prescription-only. Research-grade tirzepatide sold as a laboratory reagent is a separate regulatory category - it is not a licensed drug, not for human consumption, and not equivalent to the licensed product despite sharing the active molecule.

Research Spotlight · Tirzepatide

What is Tirzepatide? The 2026 Research Guide to the GLP-1 / GIP Dual-Agonist

May 27, 2026 · 11 min read

Tirzepatide is the single highest-volume peptide search query on Google US in 2026 outside the already-approved semaglutide brands. Roughly 12,000 monthly searches on "what is tirzepatide" alone, plus a tail of ~5,000 monthly searches on comparison and side-effect queries. The reason is straightforward: it's the active molecule behind both Mounjaro (type 2 diabetes, FDA-approved 2022) and Zepbound (chronic weight management, FDA-approved 2023), and it delivered the highest weight-loss numbers of any approved drug in trials before retatrutide arrived. This is the plain-English research guide.

RUO framing throughout. New-U supplies tirzepatide strictly as a laboratory reagent under the GLP-1 RC-T SKU. It is sold for research use only - not for human consumption, weight-loss application, or as a substitute for the licensed Mounjaro or Zepbound products. Those are prescription medicines and a separate regulatory category.

The One-Sentence Answer

Tirzepatide (development code LY3298176, by Eli Lilly) is a synthetic 39-amino-acid peptide that activates two metabolic receptors in a single molecule: the GLP-1 receptor and the GIP receptor. The dual mechanism is what separates it from semaglutide (GLP-1 only) and is the basis for the larger weight-loss percentages reported in head-to-head trials.

How Tirzepatide Compares to Semaglutide and Retatrutide

Compound	Receptor targets	Approval status	Top-dose trial weight loss
Semaglutide (Ozempic, Wegovy)	GLP-1 only	FDA: 2017 T2D, 2021 obesity	~14.9% at 68 weeks (STEP-1, 2.4mg)
Tirzepatide (Mounjaro, Zepbound)	GLP-1 + GIP (dual)	FDA: 2022 T2D, 2023 obesity	~22.5% at 72 weeks (SURMOUNT-1, 15mg)
Retatrutide	GLP-1 + GIP + Glucagon (triple)	Investigational, Phase 3	~24.2% at 48 weeks (Phase 2, 12mg)

Tirzepatide sits at the current top of the FDA-approved weight-loss league table. Retatrutide may eventually exceed it but isn't approved yet. For the molecule comparison in depth, see our companion piece on tirzepatide vs semaglutide.

What "Dual Agonist" Actually Means

The molecule is engineered to bind and activate two receptors that the body normally controls separately:

GLP-1 receptor - the same target semaglutide and liraglutide hit. Activation slows gastric emptying, suppresses appetite via the central nervous system, and improves glucose-dependent insulin secretion.
GIP receptor - the "incretin partner". GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion in response to meals and supports lipid metabolism in adipose tissue.

The historical surprise: GIP receptor activation alone was associated with weight gain in earlier research. The combination with GLP-1 activation flipped that effect - producing additional weight loss on top of what GLP-1 alone achieves. The biology is still being worked out, but the empirical signal in SURMOUNT-1 and SURMOUNT-2 was unmistakable.

The Trial Landscape

Tirzepatide has the most-developed Phase 3 evidence base of any modern peptide, with SURMOUNT covering obesity indications and SURPASS covering type 2 diabetes:

Trial	Population	Headline outcome
SURMOUNT-1	Adults with obesity, no T2D	~22.5% mean weight loss at 72 weeks (15mg)
SURMOUNT-2	Obesity + T2D	~15.7% mean weight loss + meaningful HbA1c reduction
SURMOUNT-3	Obesity, intensive lifestyle lead-in	Additional ~21.1% weight loss on top of lifestyle phase
SURMOUNT-4	Obesity, randomised withdrawal	Continued loss in treatment arm, regain in placebo arm
SURPASS-2	T2D, head-to-head vs semaglutide	Superior HbA1c + weight loss vs semaglutide 1mg
SURMOUNT-OSA	Obesity + obstructive sleep apnea	FDA approved 2024 for OSA-with-obesity indication
SUMMIT	Obesity + HFpEF heart failure	FDA approval pending for HF indication

That's a deeper evidence base than almost any other modern peptide. The combination of weight loss + cardiometabolic risk reduction + organ-specific outcomes (OSA, HFpEF) is what makes tirzepatide a "platform" molecule rather than a single-indication drug.

The Licensed Drug vs the Research Compound

This distinction matters more for tirzepatide than for most peptides because the FDA-approved versions (Mounjaro / Zepbound) are widely prescribed:

Aspect	Mounjaro / Zepbound	Research-grade tirzepatide (GLP-1 RC-T)
Regulatory status	FDA-approved prescription medicines	Research reagent only, not licensed
Manufacturing	cGMP at Eli Lilly facilities	Variable - supplier-dependent; COA is the only signal
Quality control	FDA inspection, lot release testing	Third-party HPLC + MS by Janoshik / Freedom Diagnostics
Formulation	Pre-mixed injection pen, sterile fill-finish	Lyophilised powder vial requiring reconstitution
Cost	$1,000-1,300/month US list (insurance-dependent)	Fraction of list for the raw material
Intended use	Human treatment	Laboratory research only - NOT for human use

For the broader picture of why research-grade GLP-1 supply has scaled, see our piece on online sourcing trends in the GLP-1 category.

Why the Search Interest Is Where It Is

Per Semrush US-Google data through May 2026, the tirzepatide query family looks like this:

Query	Vol/mo (US)	Intent
what is tirzepatide	12,100	Educational
tirzepatide vs semaglutide	~2,400	Comparison
does tirzepatide cause hair loss	3,600	Side effect
is mounjaro a glp 1	2,900	Branding / educational
is zepbound a glp-1	3,600	Branding / educational
compounded tirzepatide	~1,900	Sourcing / 503A

The pattern - massive educational head + significant safety-question tail + brand-name confusion - is what you'd expect for a drug that's been on the US market for less than 4 years and is going through the post-launch awareness curve.

The Side-Effect Picture

Reported adverse events in SURMOUNT-1 and SURPASS-2 were predominantly gastrointestinal and dose-dependent:

Nausea - the most common, particularly during titration
Diarrhoea, vomiting, constipation - lower frequency, also dose-dependent
Decreased appetite - expected mechanism, not classified as adverse
Hair loss (telogen effluvium) - reported in a minority, generally associated with rapid weight loss rather than the drug itself; covered in our companion piece on tirzepatide side effects research
Discontinuation rate due to adverse events was higher than placebo but lower than typical for the GLP-1 class at equivalent dose intensity

Box-warning concerns include the GLP-1 class-wide thyroid C-cell tumour signal from rodent studies (no confirmed human signal at population level), pancreatitis risk, and gallbladder disease. The full FDA prescribing information is the authoritative source for adverse-event detail.

Status check. Mounjaro and Zepbound are FDA-approved prescription medicines for licensed indications. Research-grade tirzepatide (GLP-1 RC-T) sold by New-U is a separate regulatory category - laboratory research reagent only, not licensed for human consumption or weight-loss application. Tirzepatide is also on the WADA Prohibited List (S2) and banned in any sanctioned sporting competition.

The Honest Picture for Research Buyers

The mechanism case for dual GLP-1 / GIP agonism is clinically validated. Tirzepatide is the most-evidenced peptide in modern metabolic medicine.
The trial evidence is exceptional. ~22.5% mean weight loss + best-in-class HbA1c reduction + emerging organ-specific outcomes (OSA, HFpEF, MASH).
The licensed-drug status is unambiguous: Mounjaro (T2D) and Zepbound (obesity) are FDA-approved.
The research-grade status is also unambiguous: GLP-1 RC-T is a laboratory reagent, not equivalent to the approved drugs despite sharing the active molecule.
The verification step is non-negotiable. Tirzepatide is a complex synthesised peptide; counterfeits and underdosed product are documented in the research-compound market. Janoshik / Freedom Diagnostics COAs are the only defence - how to read a COA.